Cognyte (CGNT) Q2 2027 Earnings Call Transcript

Cognyte reported Q2 FY2027 revenue of $109.2 million, up 12% year over year, while software revenue rose 20.9% to $100.8 million and non-GAAP operating income increased 52.5% to $12.2 million. Non-GAAP gross margin expanded 154bps to 73.7%, non-GAAP EPS nearly doubled to $0.15, and the company maintained FY2027 revenue guidance of about $448 million and non-GAAP operating income guidance of about $56 million. Management reaffirmed its FY2028 $500 million revenue target, supported by 85% next-12-month revenue visibility and demand for sovereign, AI-enabled intelligence platforms, though it withdrew a specific operating-cash-flow target due to higher inventory investment and supply-chain planning.

Analysis

CGNT’s equity story is shifting from a low-visibility government-project vendor toward a higher-margin software platform, but the market should not capitalize reported “recurring revenue” at SaaS multiples: a material portion is recognized upfront and is therefore not ARR. The more investable signal is operating leverage despite FX pressure; if management sustains margin expansion while converting federal proof-of-concepts into awards, consensus should begin valuing CGNT on forward operating income rather than revenue quality skepticism. The balance sheet also limits dilution and gives buybacks unusual signaling value for a subscale defense-software name.

Near-term, the key risk is not demand but conversion and cash discipline. Management effectively replaced a quantitative operating-cash-flow expectation with a qualitative one while building inventory for hardware/appliance delivery; that creates a 1-3 quarter risk of weaker cash conversion, inventory write-downs, or gross-margin pressure if government procurement slips. Declining reported RPO and volatile billings are explainable under the contract mix, but they leave investors dependent on management’s renewal assumptions; a miss in Q3 federal awards or another RPO decline without disclosed signed-deal support would challenge the visibility narrative.

The non-obvious structural beneficiary is the broader sovereign/on-prem intelligence stack rather than hyperscale AI vendors: agencies prioritizing controlled deployment favor specialized integrators and hardware-backed workflows. Conversely, this positioning can cap CGNT’s long-term gross-margin ceiling and working-capital efficiency versus cloud-native peers such as Palantir (PLTR), whose software delivery model is less exposed to appliance availability. Consensus may underappreciate that subscription migration initially suppresses reported growth and cash collection, but it should demand proof that renewals and expansion—not accounting timing—are driving the improvement.

Key Decisions for Investors

• Maintain a 1-3 month watch-to-buy on CGNT rather than chase an earnings reaction; initiate only if the next update discloses federal awards and keeps FY27 revenue/operating-income guidance intact while short-term RPO stabilizes. Upside comes from multiple re-rating on durable operating leverage; downside is a cash-flow/inventory reset.
• Use a CGNT long / PLTR short pair only after confirming CGNT trades at a material valuation discount on forward EV/operating income. The trade isolates a potential sovereign-intelligence catch-up from AI-defense software beta; stop out if CGNT misses the stated U.S. deal objective or PLTR’s commercial growth reaccelerates materially.
• Set an alert for operating cash flow and inventory in the next filing: inventory growth materially above revenue growth, or failure to produce clearly positive full-year operating cash flow, is thesis-falsifying because it would indicate hardware fulfillment is consuming the margin benefit.
• Do not infer an investment signal from NFLX or NVDA mentions; they are editorial references with no economic linkage to CGNT.